Endocrinology Evidence Evolution

5 evidence evolution narratives tracing how landmark trials and guideline updates reshaped endocrinology practice.

GLP-1 Receptor Agonists Beyond Glycemia

From glucose lowering to cardiometabolic revolution

Glucose → LEADER CV (2016) → SUSTAIN weight → SELECT obesity (2023) → MASH/CKD

From operate-for-size to molecular testing

Operate → Bethesda → molecular testing (Afirma/ThyroSeq) → active surveillance

Anabolic-first changes the game

Bisphosphonate-first → anabolic agents (SHOTZ/FRAME) → anabolic-first → sequencing

Less is more in adrenal surveillance

Operate-most → imaging characterization → conservative → reduced surveillance

From safety concern to TRAVERSE clarity

TOM safety concern (2010) → FDA warning → TRAVERSE (2023) CV neutrality